Skip to main content
Caplight Logo









Tribune Therapeutics

Tribune Therapeutics

Private
StockholmHealthcare & Life Scienceshttps://www.tribunetx.com/

Last Round

Series A

Mar 26, 2025

Total Funding Raised

$56.99M

Company Overview

Tribune Therapeutics is a biotechnology company developing a pipeline of novel medicines to treat patients with a wide range of fibrotic diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

biotechnologydrug discoveryprotein therapeuticsfibrotic diseasesbiotech startuppreclinical developmentCCN protein familyanti-fibroticdrug pipelinetherapeutic candidatebiopharmascar formationdrug licensing

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Tribune Therapeutics Comparables

Compare Tribune Therapeutics with similar companies based on industry and business-model similarity.

Tribune Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Certa Therapeutics
78%
Mediar Therapeutics
78%
Ikaika Therapeutics
73%

Tribune Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series AMar 26, 2025
SeedJun 2, 2021

Key People

Founding team and executive leadership

Ole Joergen Kaasboell

Board Observer, Chief Scientific Officer Co-founder

Founding Team

Georg Vo Beiske

Chief Executive Officer

Executive Team

Tribune Therapeutics Investors

Notable investors and investment history

Tribune Therapeutics investors
InvestorRounds
InnovestorSeries A
Inven2Seed, Series A
InvestinorSeries A
HealthCapSeries A, Seed
IndustrifondenSeries A
Novo HoldingsSeries A, Seed
LifeArc VenturesSeries A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Apr 2, 2026

    Monthly visitors grew 99% MoM, reaching 1.2K.

  • Mar 26, 2025

    $40M raised in Seed round.

Tribune Therapeutics Filings

Explore SEC and related filing metadata, where available.

Tribune Therapeutics filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Tribune Therapeutics's valuation, stock price, and market status.

Is Tribune Therapeutics a public or private company?

Tribune Therapeutics is a private company.

What is the current stock price of Tribune Therapeutics?

Tribune Therapeutics is a private company with no public stock price. No recent secondary market data is available.

How much is Tribune Therapeutics worth (valuation)?

Valuation information for Tribune Therapeutics is not publicly available.

Can I buy Tribune Therapeutics stock?

Tribune Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Tribune Therapeutics's last funding round?

Tribune Therapeutics's most recent funding round was Series A on March 26, 2025.

Who are the main investors in Tribune Therapeutics?

Key investors in Tribune Therapeutics include HealthCap, Novo Holdings, LifeArc Ventures.

Will Tribune Therapeutics IPO soon?

No public IPO plans have been announced for Tribune Therapeutics.

How can I track Tribune Therapeutics secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Tribune Therapeutics's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersStockholm
Employee Range13
Year Founded2020
Last FundingMar 26, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?